Nasus Pharma wins FDA clearance to start NS002 anaphylaxis study

• FDA cleared the IND for Nasus Pharma’s NS002 intranasal epinephrine powder, enabling a clinical study in anaphylaxis.
• Pivotal study targeted for Q4 2026; topline data expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140800PRIMZONEFULLFEED9825905) on September 14, 2026, and is solely responsible for the information contained therein.